This molecule inhibits inflammation. It might be one of the biggest stories yet for all things affected by inflammation and a ket to longevity or at least healthspan.
Additionally, a recent report indicates that over 20 pharmaceutical companies are actively working on NLRP3 protein inhibitors, with several candidates in various stages of clinical and non-clinical development.
These developments suggest that NLRP3 inhibitors are progressing through early clinical stages, with some advancing to mid-stage trials, indicating a growing interest in targeting the NLRP3 inflammasome for therapeutic purposes.